Description
United Therapeutics’ Thymmune Buyout Sparks Bigger Regenerative Medicine Ambitions!
United Therapeutics has entered another strategic lane with its acquisition of privately held preclinical biotech Thymmune Therapeutics for $140 million in cash, plus potential earn-out payments of up to $160 million tied to clinical and regulatory milestones through the end of 2031. The transaction adds Thymmune’s regenerative thymic cell therapy platform to United Therapeutics’ expanding portfolio and fits closely with its long-running focus on organ transplantation, organ alternatives, and immunomodulatory therapies. The move comes shortly after management highlighted strong late-stage momentum across its core pulmonary franchise, including Tyvaso in IPF, ralinepag in PAH, and RALDPI as a future inhaled ralinepag opportunity.
